T. De La Motte Rouge

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme

Olivier Chinot, T. De La Motte Rouge, N. Moore et al. · Advances in Therapy · 2011 · 192 citations · Full text

Medicine, Oncology, Pharmacology +14

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin et al. · Journal of Clinical Oncology · 2023 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma

Jean‐Philippe Spano, Yann Vano, Stéphane Vignot et al. · Medical Oncology · 2011 · 39 citations

Medicine, Oncology, Pharmacology +11

LBA3 Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study

N. Colombo, E. Zsiros, A. Sebastianelli et al. · Annals of Oncology · 2025 · 21 citations · Full text

Medicine, Oncology, Pharmacology +16

304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial

Jean‐Sébastien Frenel, Florence Dalenc, Barbara Pistilli et al. · Annals of Oncology · 2020 · 19 citations

Medicine, Oncology, Pharmacotherapy +13